Study of FG-M131 for relapsed or refractory T-cell lymphoma
Part of Cancer clinical trials.
This trial tests a new drug, FG-M131, for people with a type of lymphoma (T-cell lymphoma) that has come back or not improved after previous treatment. The drug targets a specific marker on cancer cells to try to stop the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with peripheral T-cell lymphoma or cutaneous T-cell lymphoma that has come back or not responded to at least one prior treatment.
- You are able to provide a tissue sample from your tumor for testing.
- You have at least one measurable tumor lesion.
- You have adequate organ function and are generally in good health (able to care for yourself and up and about).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TR115 against the standard treatment options for people with peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if TR115 can help shrink tumors and improve outcomes.
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
This trial tests a new combination of medications for mantle cell lymphoma that has returned or not responded to other treatments. The goal is to see if this combination can shrink tumors and is safe for patients like you.
This early-phase trial is testing a new drug called GNTbm-38 for people with advanced solid tumors or a type of lymphoma called peripheral T-cell lymphoma (PTCL) that hasn't responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests a new experimental antibody therapy for people with certain types of peripheral T-cell lymphoma that have not responded to or have come back after prior treatment. The study aims to see if the treatment is safe and effective.
This trial tests a new oral drug, TT-01488, taken with a standard antibody treatment (rituximab) for mantle cell lymphoma. It may help people who have either not been treated yet or whose cancer has returned, and aims to improve outcomes with fewer side effects.
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.